Last reviewed · How we verify

NCT06826131

Determination of the Optimal Cut Off Value of the Modified Ashworth Scale in the Evaluation of Gait Performance and Functional Mobility in Individuals With Cerebral Palsy

Completed Last updated 22 August 2025
What this trial tests

trial in Cerebral Palsy (CP) in 25 participants. Completed in 10 May 2025.

Timeline
8 February 2025
Primary endpoint
10 April 2025
10 May 2025

Quick facts

Lead sponsorInonu University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment25
Start date8 February 2025
Primary completion10 April 2025
Estimated completion10 May 2025
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Inonu University

Who can join

Adults 6 to 15, any sex, with Cerebral Palsy (CP) or Walking Performance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The spastic type, which is the most common type of CP, constitutes approximately 75% of individuals. The most prominent physical examination finding in patients with CP is marked tonus changes. Increased tonus and involuntary movement patterns are frequently observed clinically. Today, the Modified Ashworth Scale is mostly used in the evaluation of spasticity in individuals. Ashworth scale was defined in 1964 and modified in 1987. This scale was developed to assess muscle tone. Resistance to passive movement is evaluated and scored between 0-4.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cerebral Palsy (CP)

Currently open trials in the same condition.

Other Inonu University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06826131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing